Condition: Myelofibrosis · Sponsor: Sumitomo Pharma America, Inc.
This study is a Phase 1/2, multicenter, dose-escalation, open-label trial to assess safety, tolerability, pharmacokinetics and pharmacodynamics of nuvisertib (TP-3654) in patients with intermediate or high-risk primary or secondary MF.
This description comes directly from the study's public registry record.
Reyna Bishop · 617-674-6800 · reyna.bishop@us.sumitomo-pharma.com
Jordan Simpson · jordan.simpson@us.sumitomo-pharma.com
Always discuss trial participation with your own doctor first.
| University of Alabama | Birmingham, Alabama, United States | Recruiting |
| The University of Arizona Cancer Center | Tucson, Arizona, United States | Recruiting |
| City of Hope | Duarte, California, United States | Recruiting |
| University of Southern California | Los Angeles, California, United States | Recruiting |
| Hoag Family Cancer Institute | Newport Beach, California, United States | Recruiting |
| Blood Cancer Center | Denver, Colorado, United States | Recruiting |
| Yale School of Medicine | New Haven, Connecticut, United States | Recruiting |
| University of Florida Health Shands Cancer Hospital | Gainesville, Florida, United States | Completed |
| University of Miami | Miami, Florida, United States | Recruiting |
| Baptist Health - Miami Cancer Institute | Miami, Florida, United States | Recruiting |
| Emory University | Atlanta, Georgia, United States | Recruiting |
| University of Chicago | Chicago, Illinois, United States | Recruiting |
+ 72 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT04176198